ICICI Direct is bullish on Zydus Wellness recommended buy rating on the stock with a target price of Rs 2000 in its research report dated February 03, 2023.

Sharekhan is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 1740 in its research report dated February 02, 2023.

The impact of price hikes to mitigate inflationary pressure would be reflected from the fourth quarter onwards in the consumer wellness segment, which accounted for 10% of total revenues in the third quarter, the company said in an exchange filing.

“Options data suggests a shift in the trading range in between 17600 to 18300 zones while an immediate trading range in between 17700 to 18200 zones,” Chandan Taparia, Analyst-Derivatives at Motilal Oswal Financial Services Limited, said.

“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near term, there are multiple assets waiting to play out. For Cipla this year, we are hoping to see generic Advair, generic Abraxane which is most likely in the price but beyond that, there will be a generic Qvar, there will be a generic Teriparatide and potentially a generic Flovent as well.”

ICICI Direct is bullish on Zydus Wellness recommended buy rating on the stock with a target price of Rs 2100 in its research report dated November 11, 2022.

Zydus Wellness Ltd., incorporated in the year 1994, is a Mid Cap company (having a market cap of Rs 10414.04 Crore) operating in FMCG sector.

Zydus Wellness has recently given a triangle pattern breakout near its long term support area on the weekly timeframe. The 200 EMA is at Rs 1,680 and the stock is comfortably sustaining above it, which can be used as a confluence to the bullish view.

Anand Rathi is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2140 in its research report dated September 23, 2022.

Zydus Wellness Ltd., incorporated in the year 1994, is a Mid Cap company (having a market cap of Rs 10110.19 Crore) operating in FMCG sector.

Zydus Wellness Ltd., incorporated in the year 1994, is a Mid Cap company (having a market cap of Rs 10416.58 Crore) operating in FMCG sector.

Zydus initiated the Class II voluntary recall on July 15 this year. Similarly, Baltimore-based Lupin Pharmaceuticals, Inc, is recalling 7,872 bottles of Rifampin Capsules, a medication used to treat infections caused by bacteria.

The drug, touted as a potential blockbuster drug for the German pharmaceutical firm, will be sold under the brand name Kerendia in India.

"The major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end-stage renal disease or kidney failure. Despite therapy, these patients often progress to kidney failure.

Vijender Singh was most recently CEO of Metropolis Healthcare and COO of Dr. Lals Pathlabs, where Vijender helped scale both these companies under private equity ownership.

Sectorally, buying was seen in realty, utilities, power, consumer discretionary, and consumer durables while selling was visible in healthcare, IT, oil & gas, and energy stocks.

ICICI Direct is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2100 in its research report dated July 31, 2022.

Sharekhan is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated July 29, 2022.

"The company is confident to drive growth and increase the market share of its brands through innovation, leveraging distribution channels and expanding the brand portfolio," said Zydus Wellness.

Physical reopening of educational institutions has thrown a lifeline to categories such as stationeries and school shoes that were hit hard by Covid-19 and study from home, while impulse categories like packaged snacks and confectionery have got a boost amid an overall slowdown in discretionary spending.

Each episode is an exclusive interview, which is available on O4S Labs, the companys YouTube channel.

Sharekhan is bullish on Zydus Wellness has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated May 17, 2022.

Executives said they may have to push the next round of price hike as early as this month itself despite the last price hike undertaken in end-March or April with the falling rupee impacting their immediate consignment of goods coming into the country.

Net Sales are expected to increase by 12.8 percent Y-o-Y (up 76 percent Q-o-Q) to Rs. 683.2 crore, according to ICICI Direct.

ICICI Securities is bullish on Zydus Wellness recommended buy rating on the stock with a target price of Rs 2250 in its research report dated April 02, 2022.

Emami has historically used an inorganic route to growth including the acquisition of Zandu (2009), Kesh King (2015) and German brand Creme 21 (2019). These brands or businesses have over the years emerged as major brands for the company.

The drug regulator had on August 20 given emergency use authorisation (EUA) to the three-dose Covid-19 vaccine, the first in India that can be given to people 12 years and above.